Clinical trial
Assessment and Tracking of Long-term Alefacept Safety
NCT00454701 · Astellas Pharma Inc, Industry · Terminated
Key facts
| NCT number | NCT00454701 |
|---|---|
| Title | Assessment and Tracking of Long-term Alefacept Safety |
| Official title | Assessment and Tracking of Long-term Alefacept (LFA-3/IgG1 Fusion Protein) Safety (ATLAS) |
| Acronym | ATLAS |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Terminated |
| Study type | Observational |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Alefacept exposure |
| Enrollment | 1,897 |
| Start date | Jun 1, 2003 |
| Primary completion | Feb 1, 2012 |
| Completion | Feb 1, 2012 |
| First posted | Apr 2, 2007 |
| Last update posted | Dec 11, 2013 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: